SCHEMBL5848780

SCHEMBL5848780

CC(C)(C)OC(=O)N1CCN(Cc2ccccc2)c2ccccc2C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 2/20 0.61
CACNA1H O95180 2/20 0.61
CACNA1I Q9P0X4 2/20 0.61
HDAC1 Q13547 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
MAPK1 P28482 1/20 0.52
LIPG Q9Y5X9 1/20 0.50
BRD4 O60885 1/20 0.48
NAMPT P43490 2/20 0.46
BCHE P06276 1/20 0.46
HTR6 P50406 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
BRS3 P32247 1/20 0.45
ESR2 Q92731 1/20 0.44
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
NR1H2 P55055 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15522788 0.89 CACNA1G (0.49) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL537598 0.87 CACNA1G (0.47) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL5848129 0.87 MAPK1 (0.53) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL5848536 0.84 MAPK1 (0.53) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL1049753 0.84 HDAC1 (0.50) HDAC1HDAC6MAPK1LIPGOPRD1
SCHEMBL5849071 0.83 MAPK1 (0.52) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL5849947 0.83 MAPK1 (0.52) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL8399553 0.83 MAPK1 (0.48) HDAC1HDAC6MAPK1LIPGHDAC8
SCHEMBL6616760 0.81 MAPK1 (0.47) CACNA1GCACNA1HCACNA1IHDAC1HDAC6
SCHEMBL5849968 0.81 MAPK1 (0.49) MAPK1LIPGNAMPTESR2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7008938-B2 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient NOKIA CORPORATION (FI) 2006-03-07 US disclosed
US-20050009755-A1 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. 2005-01-13 US disclosed
US-6809092-B2 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-10-26 US disclosed
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient NOKIA CORPORATION (FI) 2003-08-28 US disclosed
EP-1254898-A1 BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient BACH1, BACE1, CMA1 CACNA1G 732/4885CACNA1H 1295/4885CACNA1I 633/4885
US-20050009755-A1 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient BACE1, BACE2, CBS CACNA1G 679/4885CACNA1H 1272/4885CACNA1I 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.